SpliSense Receives FDA Fast Track Designation for SPL84 for the Treatment of Cystic Fibrosis

JERUSALEM, May 29, 2024 /PRNewswire/ — SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including cystic fibrosis (CF), muco-obstructive diseases like COPD, asthma and NCFB and idiopathic pulmonary…